Novartis AG (SWX:NOVN)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 228.90B +28.1% |
| Revenue (ttm) | 44.94B +9.6% |
| Net Income | 11.09B +17.1% |
| EPS | 5.67 +21.8% |
| Shares Out | 1.91B |
| PE Ratio | 21.16 |
| Forward PE | 17.24 |
| Dividend | 3.70 (3.08%) |
| Ex-Dividend Date | Mar 10, 2026 |
| Volume | 258,548 |
| Average Volume | 3,199,355 |
| Open | 120.54 |
| Previous Close | 119.96 |
| Day's Range | 120.54 - 121.34 |
| 52-Week Range | 81.10 - 121.24 |
| Beta | 0.46 |
| RSI | 72.65 |
| Earnings Date | Feb 4, 2026 |
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland, the United States, China, Germany, and internationally. It focuses on developing products in cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and other therapeutic areas. The company offers Entresto, an angiotensin receptor-neprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, a... [Read more]
Financial Performance
In 2025, Novartis AG's revenue was $56.67 billion, an increase of 9.57% compared to the previous year's $51.72 billion. Earnings were $13.98 billion, an increase of 17.11%.
Financial numbers in USD Financial StatementsNews
Oakmark International Strategy Q4 2025 New Investments And Divestments
Oakmark International Strategy Q4 2025 New Investments And Divestments
Novartis (NVS) Launches Major Biomedical Center in San Diego
Novartis (NVS) Launches Major Biomedical Center in San Diego
Novartis breaks ground on new R&D center in San Diego
Novartis breaks ground on a 466,000-sq-ft AI-driven San Diego research center, part of a $23B US expansion. Read more here.
Novartis (NVS) Initiates Construction of New Biomedical Research Hub in San Diego
Novartis (NVS) Initiates Construction of New Biomedical Research Hub in San Diego
Novartis: Value Price, Growth Pipeline
Novartis (NVS) offers a compelling value opportunity with EPS growth, margin expansion, and a robust pipeline at a discounted multiple.
Novartis AG 2025 Q4 - Results - Earnings Call Presentation
2026-02-05. The following slide deck was published by Novartis AG in conjunction with their 2025 Q4 earnings call.
Novartis AG (NVS) Q4 2025 Earnings Call Transcript
Novartis AG (NVS) Q4 2025 Earnings Call Highlights: Strong Full-Year Growth Amidst Q4 Challenges
Novartis AG (NVS) Q4 2025 Earnings Call Highlights: Strong Full-Year Growth Amidst Q4 Challenges
Q4 2025 Novartis AG Earnings Call Transcript
Q4 2025 Novartis AG Earnings Call Transcript
Novartis Faces Biggest Patent Expiry Ever but Sees Growth Ahead
Swiss pharmaceutical Novartis AG (NYSE: NVS) reported fourth-quarter 2025 results on Wednesday. The company's net sales rose 1% year over year to $13.34 billion, missing Wall Street's consensus estim...
Novartis Faces Biggest Patent Expiry Ever but Sees Growth Ahead
Swiss pharmaceutical Novartis AG (NYSE: NVS) reported fourth-quarter 2025 results on Wednesday.
Growth guidance remains 'fully intact,’ says Novartis CEO Vas Narasimhan
Novartis CEO Vas Narasimhan joins 'Money Movers' to discuss drug pricing, competition from generic drugmakers, and more.
Watch CNBC's full interview with Novartis' Vas Narasimhan
Novartis CEO Vas Narasimhan joins 'Money Movers' to discuss drug pricing, competition from generic drugmakers, and more.
Novartis CEO: U.S. drug pricing rules could impact launches in Europe
Novartis CEO Vas Narasimhan tells CNBC the company doesn’t expect near‑term effects from President Trump’s “most favoured nation” drug‑pricing order. But he warns the policy could slow new drug launch...
Novartis (NVS) Announces 2026 Dividend Proposal
Novartis (NVS) Announces 2026 Dividend Proposal
Novartis (NVS) Projects Slight Decline in Core Operating Income for FY26
Novartis (NVS) Projects Slight Decline in Core Operating Income for FY26
Novartis (NVS) Reports Robust Q4 Sales Growth and Pipeline Advancements
Novartis (NVS) Reports Robust Q4 Sales Growth and Pipeline Advancements
Earnings Scheduled For February 4, 2026
Companies Reporting Before The Bell • Oaktree Specialty Lending (NASDAQ: OCSL) is projected to report quarterly earnings at $0.38 per share on revenue of $75.31 million. • Ares Capital (NASDAQ: ARCC ...
Novartis (NVS) Q4 Earnings Beat Estimates Despite Revenue Miss
Novartis (NVS) Q4 Earnings Beat Estimates Despite Revenue Miss
Novartis (NVS) Proposes 5.7% Dividend Increase for 2025
Novartis (NVS) Proposes 5.7% Dividend Increase for 2025
Novartis Sales Rise Despite Generic Drug Competition in U.S.
The pharma major said it had strong results in 2025, but guided toward a decline in core operating profit this year.
Novartis proposes dividend raise to CHF 3.70
Novartis Q4 Profit Down, Sales Rise; Sees Higher Sales In FY26
(RTTNews) - Swiss drug major Novartis AG (NVS) reported Wednesday lower profit in its fourth quarter, despite sales growth. Further, the company lifted dividend, and issued fiscal 2026 outlook, expect...
Novartis expects low single-digit decline in 2026 operating profit
Swiss drugmaker Novartis forecast a decline in 2026 operating profit in the low single-digit percentage range on Wednesday, held back by competition from cheaper copies of established products such as...